MondegarAI
Lion Point Capital, LP

Q1 2025 · 13F-HR

Lion Point Capital, LPholdings as filed

Filed 2025-05-15 · accession 0001013594-25-000673

$15.7M
Reported value
21
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
457669307INSMINSMED INC$2.3M14.8%30,500CommonSOLE
039697107ARDXARDELYX INC$1.6M10.5%335,400CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$1.3M8.00%79,000CommonSOLE
31447P100FENCFENNEC PHARMACEUTICALS INC$1.2M7.60%195,700CommonSOLE
G52694109KNSAKINIKSA PHARMACEUTICALS LTD$1.0M6.50%45,900CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$898,8205.73%26,000CommonSOLE
08205P209BNTCBENITEC BIOPHARMA INC$806,6205.15%62,000CommonSOLE
374163103GERNGERON CORP$795,0005.07%500,000CommonSOLE
G29687103AVDLAVADEL PHARMACEUTICALS PLC$772,8214.93%98,700CommonSOLE
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$724,1324.62%46,300CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$675,6754.31%55,000CommonSOLE
471871202JSPRJASPER THERAPEUTICS INC$629,9504.02%146,500CommonSOLE
G1110E107BHVNBIOHAVEN LTD$545,7083.48%22,700CommonSOLE
254604101IRONDISC MEDICINE INC$526,1843.36%10,600CommonSOLE
59935V107MISTMILESTONE PHARMACEUTICALS IN$439,1002.80%548,806CommonSOLE
75901B107RGNXREGENXBIO INC$412,9132.63%57,750CommonSOLE
09609G209BLE0BLUEBIRD BIO INC$385,0912.46%78,912CommonSOLE
81750R102MCRB1EURSERES THERAPEUTICS INC$238,5331.52%340,761CommonSOLE
59045L106MERSANA THERAPEUTICS INC$221,6651.41%644,000CommonSOLE
44486Q103HUMAHUMACYTE INC$142,3680.91%83,500CommonSOLE
85209E109SPRUCE BIOSCIENCES INC$21,7580.14%75,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.